3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Neoplasms
4
Recurrence
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinal Cord Neoplasms
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Glioma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Diseases
1
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
abemaciclib
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled